Research record

The scientific record

Peer-reviewed publications and registered clinical studies across peptide science. Records are retrieved from independent public databases and link directly to their original source.

Publications indexed

Clinical studies

23 Oct 2026

Records updated

Latest publications

1,426 matching records on PubMed

PubMedEndocrinology and metabolism clinics of North America2026 Dec

GLP-1 Receptor Agonists and Reproductive Health: Implications for Contraception, Fertility, and Pregnancy

Porterfield F, Mulligan J, Salim K, Olubowale O + 1 more

Review

PMID 42907053

View on PubMed

PubMedNorth American Spine Society journal2026 Dec

GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk

Ferraz VR, Dawoud B, Mercier PA, Mattei TA

Review

PMID 42871273

View on PubMed

PubMedAmerican journal of preventive cardiology2026 Dec

Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program

Patel A, Trivedi L, Prasad R, Avennati E + 4 more

PMID 42828252

View on PubMed

PubMedPulmonology2026 Dec

Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network

Testelmans D, Bonsignore MR, Pataka A, Fanfulla F + 5 more

Multicenter Study

PMID 42639925

View on PubMed

PubMedAppetite2026 Dec 1

One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy

Gao SX, Borner T

Review

PMID 42492687

View on PubMed

PubMedBiochemical and biophysical research communications2026 Nov 5

Incretin signaling suppresses high glucose-induced β-cell hypoxia through a cAMP/PKA-dependent mechanism

Saranaruk P, Sato Y, Tsuruta M, Yamagata K

PMID 42790025

View on PubMed

PubMedJournal of the Endocrine Society2026 Nov

Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy

Ruan F, Gnana B, Mei C, Gong W + 3 more

Review

PMID 42857401

View on PubMed

PubMedJournal of diabetes and its complications2026 Nov

Switching from glucagon-like peptide-1 receptor agonists to tirzepatide in type 2 diabetes: does therapeutic sequencing matter for metabolic dysfunction-associated steatotic liver disease?

Patoulias D, Muzurović E, Rizzo M, Mantzoros CS

Editorial

PMID 42772979

View on PubMed

PubMedDiabetes, obesity & metabolism2026 Nov

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics

Samuels JM, Williams CR, Patel MB, Self WH + 9 more

Clinical Trial Protocol

PMID 42712125

View on PubMed

PubMedThe lancet. Diabetes & endocrinology2026 Nov

From adiposity to multisystem morbidity: the case for weight loss as disease modification

Sattar N, Ferguson LD, Lee MMY

Review

PMID 42660161

View on PubMed

PubMedDiabetes, obesity & metabolism2026 Nov

Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial Emulation

Chen SC, Huang YN, Li PY, Chen JC + 3 more

PMID 42642357

View on PubMed

PubMedJournal of the American Academy of Dermatology2026 Nov

Highlights from JAAD Reviews: Skin in the Game: Dermatologic and Medicolegal Aspects of Glucagon-Like Peptide-1 Receptor Agonists

Lipner SR

Editorial

PMID 42637047

View on PubMed

Clinical studies

257 registered records on ClinicalTrials.gov

ClinicalTrials.govNCT07889453

Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide

Active Not Recruiting
Observational
Drug

Sponsor: LMC Diabetes & Endocrinology Ltd.
Enrollment: 650 participants
Study status: Active Not Recruiting
Last updated: 22 Oct 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

ClinicalTrials.govNCT07889648

A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications

Phase3
Not Yet Recruiting
Interventional
Combination Product

Sponsor: Hoffmann-La Roche
Enrollment: 948 participants
Study status: Not Yet Recruiting
Last updated: 22 Oct 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

ClinicalTrials.govNCT07107334

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

Phase2
Recruiting
Interventional
Drug

Sponsor: University of Florida
Enrollment: 20 participants
Study status: Recruiting
Last updated: 21 Oct 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

ClinicalTrials.govNCT06751589

A Study of a Weight Loss Intervention in People With Endometrial Cancer

Early Phase1
Active Not Recruiting
Interventional
Drug

Sponsor: Memorial Sloan Kettering Cancer Center
Enrollment: 4 participants
Study status: Active Not Recruiting
Last updated: 21 Oct 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

ClinicalTrials.govNCT07574723

Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity

Recruiting
Interventional
Drug

Sponsor: Dasman Diabetes Institute
Enrollment: 68 participants
Study status: Recruiting
Last updated: 20 Oct 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

ClinicalTrials.govNCT07874828

PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study

Phase2
Recruiting
Interventional
Drug

Sponsor: M.D. Anderson Cancer Center
Enrollment: 30 participants
Study status: Recruiting
Last updated: 20 Oct 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

ClinicalTrials.govNCT07881458

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Phase3
Not Yet Recruiting
Interventional
Drug

Sponsor: Eli Lilly and Company
Enrollment: 1,000 participants
Study status: Not Yet Recruiting
Last updated: 19 Oct 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

ClinicalTrials.govNCT07881432

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

Phase3
Not Yet Recruiting
Interventional
Drug

Sponsor: Eli Lilly and Company
Enrollment: 2,115 participants
Study status: Not Yet Recruiting
Last updated: 19 Oct 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

About the research library

Research records displayed within the Avion Science Research Library are retrieved from independent public scientific databases including PubMed and ClinicalTrials.gov. Inclusion within this library does not imply endorsement by Avion Science and does not establish the safety, efficacy or intended use of any Avion Science product. Information is provided for scientific and educational purposes and users should refer to the original source for complete study information.

PubMed and ClinicalTrials.gov are independent third-party resources and are not affiliated with Avion Science.